Navigation Links
ArjoHuntleigh and Ossur Formalize Distribution Agreement to Deliver DVTCare at Home Program
Date:11/12/2013

provider of equipment and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. Equipment, service and technologies are supplied under the brands ArjoHuntleigh for patient handling and hygiene, disinfection, DVT prevention, medical beds, therapeutic surfaces and diagnostics, GETINGE for infection control and prevention within healthcare and life science and MAQUET for surgical work places, cardiopulmonary and critical care. ArjoHuntleigh offers a broad range of integrated solutions for the care of people with reduced mobility and related conditions, with the aim to enhance the quality of care in elderly care facilities, hospitals and other healthcare environments. More information about ArjoHuntleigh can be found at www.ArjoHuntleigh.com.

Contact:
Chris Ryan, Senior Marketing Manager
ArjoHuntleigh
630.785.4537
Christopher.Ryan@ArjoHuntleigh.com

1 Hirsh, J and Hoak, J. Management of Deep Vein Thrombosis and Pulmonary Embolism: A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association. Circulation. 1996; 93: 2212-2245.

2 Tapson VF. Acute pulmonary embolism. N Engl J Med. Mar 6 2008; 358(10):1037-52.


'/>"/>
SOURCE ArjoHuntleigh
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ArjoHuntleigh Names Rick Lytle As President North America
2. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
3. Misonix Announces New Distribution Agreement For Panama
4. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
5. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
6. Coping With New FDA Mandates For Drug Sample Distribution
7. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
8. EnerJel™ Adds 200 Independent Pharmacies To Distribution Base
9. Cephasonics Inks Distribution Deal With Tritech To Extend Worldwide Sales Reach Into Israel
10. PolyOne Announces Expansion in Costa Rica with Healthcare-Focused Distribution Services
11. Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 /CNW/ - Covalon Technologies Ltd. (the ... technologies company, is delighted to announce its financial ... 2015, which includes revenue for three months of ... $264,340. Revenue from advanced wound care product sales for ... increased 24% to $1,742,672 compared to $1,400,065 for ...
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... May 02, 2007 /PRNewswire/ -- Ceregene, Inc.,today presented interim ... gene therapy product designed to deliver nerve growth,factor (NGF) ... follow-up, the results for the six patients who received,CERE-110 ... the,therapy was well tolerated, and an interim analysis suggested ...
... CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - ... sclerosis (RRMS),patients treated with COPAXONE(R) (glatiramer ... experienced a,90 percent reduction in magnetic ... their baseline. These benefits were,achieved early ...
Cached Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
(Date:5/29/2015)... NJ (PRWEB) May 30, 2015 ... ever changing local and federal regulations, we provide ... of their patients who are suffering from pain, ... says Srinivas Nalamachu, MD, professor of rehabilitation medicine ... Institute in Overland Park, Kansas. , A new ...
(Date:5/29/2015)... 2015 What does community do? , ... community comes together to plant gardens, to teach young ... awareness of critical issues. Community invites everyone to help ... , "What Community Does" was commissioned by The Denver ... and released during the foundation’s Annual Celebration in May. ...
(Date:5/29/2015)... Rhode Island (PRWEB) May 29, 2015 ... 7, 2015. The event, now closed to new registration, ... Fort Adams. This exciting competitive running event demonstrates ... organizations to create a public benefit – in this ... scenic coastal views around the famed Ocean Drive and ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... 2015 According to a recent HealthDay article, ... workers has a substance abuse problem - the data, which ... adults with full-time jobs, revealed that 9.5% of those workers ... (1) The National Council on Alcoholism and Drug Dependence (NCAAD) ... an estimated 70% of the 14.8 million illicit drug users ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4
... Caused Public Health CrisisEditor,s Note: Complete report including ... . WASHINGTON, Jan. 13 The American Lung ... 2008 report today, which includes a report ... federal laws to protect citizens from tobacco caused ...
... groundbreaking case that could,affect one-third of American families, Cook ... a 10 month old child with a severe heart,condition ... also gave the,father custody of his 3 year old ... unusual because most courts have not recognized stepfathers,as having ...
... Tenn., Jan. 13 The National Eczema Association (NEA) ... and Theraplex Clear Lotion .The NEA Seal ... Sensitive-Skin Education (EASE) program, which is intended to improve ... eczema and sensitive skin. "These products met our criteria ...
... meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical has ... season beginning in August. , ... (Vocus) January 13, ... Flu Vaccine for the 2009-2010 flu season. They ...
... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ... Julia M. Fisher, Western Medical Product Manager. , ... Westlake, OH (PRWEB) ... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ...
... New research out of Wake Forest University Baptist Medical ... used to relieve symptoms of cough and congestion, may ... , The study appears in this month,s issue ... American College of Chest Physicians, and reports that the ...
Cached Medicine News:Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 2Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 3Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Low Cost Oxygen Regulator: Pay Less For Quality 2Health News:Popular cold and cough treatment may create respiratory distress in young children 2Health News:Popular cold and cough treatment may create respiratory distress in young children 3
1.2% Tryptone, 2.4% Yeast Extract, 1.6% Glycerol, 100 ml of 10x Phosphate buffer supplement....
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
Medicine Products: